58.25
-1.40 (-2.35%)
| Penutupan Terdahulu | 59.65 |
| Buka | 59.00 |
| Jumlah Dagangan | 1,548,042 |
| Purata Dagangan (3B) | 2,044,067 |
| Modal Pasaran | 17,160,423,424 |
| Harga / Jualan (P/S) | 14.57 |
| Harga / Buku (P/B) | 4.45 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2025 |
| Margin Keuntungan | -120.35% |
| Margin Operasi (TTM) | -62.30% |
| EPS Cair (TTM) | -2.16 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,284.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.43% |
| Nisbah Semasa (MRQ) | 3.30 |
| Aliran Tunai Operasi (OCF TTM) | -789.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -565.77 M |
| Pulangan Atas Aset (ROA TTM) | -10.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -18.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | KEYMED BIO-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.13 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| KEYMED BIO-B | 17 B | - | - | 4.45 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
| HENLIUS | 36 B | - | 38.76 | 9.00 |
| INNOCARE | 23 B | - | - | 3.00 |
| ASCENTAGE-B | 17 B | - | - | 21.49 |
| EVEREST MED | 13 B | - | - | 2.92 |
|
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 29.68% |
| % Dimiliki oleh Institusi | 29.11% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |